Evidence map›Paper›PMID 21406403›Full record

ArticleCancer research2011

Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma.

Bilal Bin Hafeez, Weixiong Zhong, Jamey Weichert, Nancy E Dreckschmidt, Mohammad Sarwar Jamal, Ajit K Verma

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Identification of Myeloid Protein Kinase C Epsilon as a Novel Atheroprotective Gene.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Impact of Vimentin on Regulation of Cell Signaling and Matrix Remodeling.Frontiers in cell and developmental biology · 2022
    Review
  10. Article
  11. Article
  12. Molecular targets of pomegranate (Iranian journal of basic medical sciences · 2019
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Protein kinase C: perfectly balanced.Critical reviews in biochemistry and molecular biology · 2018
    Review
  20. Protein kinase C as a tumor suppressor.Seminars in cancer biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Bilal Bin HafeezDepartment of Human Oncology, Wisconsin Institute of Medical Research, Paul Carbone Comprehensive Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53792, USA.
Weixiong Zhong
Jamey Weichert
Nancy E Dreckschmidt
Mohammad Sarwar Jamal
Ajit K Verma
William S. Middleton Memorial Veterans Hospital · USUniversity of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Role of PKC in Tumor PromotionR01CA035368 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI VERMA, AJIT K · 1985 to 2011
$3.6M
Novel Inhibitors of Prostate Cancer ProgressionR01CA138761 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI VERMA, AJIT K · 2010 to 2014
$1.5M
NCI NIH HHS 2 P30 CA014520-34NCI NIH HHS CA35368NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA035368NCI NIH HHS R01 CA138761
6 · The paper itself

Abstract

Protein kinase C epsilon (PKCε), a novel PKC isoform, is overexpressed in prostate cancer (PCa) and correlates with disease aggressiveness. However, the functional contribution of PKCε to development or progression of PCa remained to be determined. Here we present the first in vivo genetic evidence that PKCε is essential for both the development and metastasis of PCa in the transgenic mouse model of prostate adenocarcinoma (TRAMP). Heterozygous or homozygous genetic deletions of PKCε in FVB/N TRAMP inhibited PCa development and metastasis as analyzed by positron emission tomography/computed tomography, tumor weight determinations, and histopathology. We also examined biomarkers associated with tumor progression in this model, including markers of survival, proliferation, angiogenesis, inflammation, and metastatic progression. To find clues about the genes regulated by PKCε and linked to the Stat3 signaling pathway, we carried out focused PCR arrays of JAK/STAT signaling in excised PCa tissues from PKCε wild-type and nullizygous TRAMP mice. Notably, PKCε loss was associated with significant downregulation of proliferative and metastatic genes C/EBPβ (CCAAT/enhancer binding protein β), CRP (C-reactive protein), CMK, EGFR (epidermal growth factor receptor), CD64, Jun B, and gp130. Taken together, our findings offer the first genetic evidence of the role of PKCε in PCa development and metastasis. PKCε may be potential target for prevention and/or treatment of PCa.

Indexed as

Disease Models, AnimalAdenocarcinomaAnimalsC-Reactive ProteinErbB ReceptorsFemaleGene ExpressionHumansImmunoblottingJanus KinasesMaleMiceMice, KnockoutMice, TransgenicNeoplasm MetastasisPositron-Emission TomographyC-Reactive ProteinErbB ReceptorsJanus KinasesProtein Kinase C-epsilonStat3 protein, mouseSTAT3 Transcription Factor

Identifiers

PMID21406403
PMCPMC3059775
OpenAlexW2167744080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.